Navigation Links
ThromboGenics NV - Q3 2009 Business Update
Date:11/4/2009

the potential to be a very important new entrant into the anticoagulant market. TB-402 is a recombinant human monoclonal antibody that partially inhibits Factor VIII, a key component of the coagulation cascade. This novel mode of action is expected to reduce the risk of undesirable bleeding events, even at high doses, as well as the need for patient monitoring. These are the two main drawbacks associated with current anticoagulant therapy. In addition, TB-402 is a long-acting agent, which means it could be given as a single dose to prevent the development of DVT in patients undergoing surgery. This would be an attractive option, as all current anticoagulant treatment options require daily treatment for up to several weeks.

ThromboGenics and its partner BioInvent plan to out-license TB-402 for its later stage development and commercialization. This out-licensing strategy is driven by the large sales potential of the product and the broad range of prescribers that could use an anticoagulant with TB-402's unique profile.

    TB-403 (RG7334) - Novel anti-cancer agent partnered with Roche

    - TB-403 Phase Ib results to be presented at the American
      Association for Cancer Research (AACR) Conference
    - ThromboGenics continues to build a strong relationship with Roche

The clinical development of TB-403 is progressing as planned and the results of a Phase Ib trial are to be presented at the AACR conference in Boston, MA USA on November 15-19, 2009. The Phase Ib trial was designed to assess TB-403's tolerability, pharmacokinetics and pharmaco-dynamics in patients with advanced cancer.

In June 2008, ThromboGenics and its co-development partner BioInvent signed a strategic alliance deal with Roche for its novel anti-cancer agent, TB-403 (anti-PlGF). In January, 2009, ThromboGenics and BioInvent received their first success fee from Roche based on the successful transfer and implementation of technology and
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
2. ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
3. ThromboGenics NV Announces Business Update and Half Year Results 2009
4. ThromboGenics NV: Business Update
5. ThromboGenics Announces Business Update and 2008 Full Year Results
6. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
7. ThromboGenics N.V.: Business Update
8. ThromboGenics Announces Half Year Results 2008
9. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
10. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 2013 was a ... Brain State Technologies®. They saw continued independent research led ... who were awarded a $1 million grant from the ... “Brain and Behavior” a peer reviewed journal, Amy Grant ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... Diego, CA (PRWEB) January 14, 2014 ... on the products of cells grown under simulated embryonic ... international license agreement with Suneva Medical, Inc. for physician-dispensed ... (CCM). , This agreement is an amendment ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... , , , , Martin Simon, ... Martin Simon, Petra Albrecht, and Helmut J. Schmidt, University of Kaiserslautern, , ... AG , , Introduction ... the surface , antigen expression of Paramecium primaurelia individual cells ...
... , , , Abstract , ... method that allows researchers to determine , the presence, structure and ... tissue or cell of interest. The basic protocol involves the , ... by amplification of the gene(s) of interest. Due to buffer incompatibilities, , ...
... , Multiporator , , , , , , , ... Protocol No. 4308 915.037 11/1999 , , , ... , Cell line , ... Transfection with , Plasmid pEGFP-N1 (in bidistilled H 2 O), , ...
Cached Biology Technology:Single-cell RT-PCR Analysis of Paramecium Primaurelia with the Eppendorf , cMaster RTplusPCR System 2Single-cell RT-PCR Analysis of Paramecium Primaurelia with the Eppendorf , cMaster RTplusPCR System 3Single-cell RT-PCR Analysis of Paramecium Primaurelia with the Eppendorf , cMaster RTplusPCR System 4Single-cell RT-PCR Analysis of Paramecium Primaurelia with the Eppendorf , cMaster RTplusPCR System 5Single-cell RT-PCR Analysis of Paramecium Primaurelia with the Eppendorf , cMaster RTplusPCR System 6Single-cell RT-PCR Analysis of Paramecium Primaurelia with the Eppendorf , cMaster RTplusPCR System 7cMaster RTplusPCR System for increased sensitivity and product length , in RT-PCR 2cMaster RTplusPCR System for increased sensitivity and product length , in RT-PCR 3cMaster RTplusPCR System for increased sensitivity and product length , in RT-PCR 4cMaster RTplusPCR System for increased sensitivity and product length , in RT-PCR 5cMaster RTplusPCR System for increased sensitivity and product length , in RT-PCR 6U937 2
(Date:4/17/2014)... such as heart disease, epilepsy and pain, making them ... is still much scientists do not know about the ... into the structure of sodium channels and, specifically, one ... responsible for ,fine-tuning, the activity of the channel. The ... the Journal of Biological Chemistry . , Nerves ...
(Date:4/17/2014)... journal Current Biology on April 17 have ... The Brazilian insects, which represent four distinct but related ... first example of an animal with sex-reversed genitalia. ... different animals, Neotrogla is the only example ... Kazunori Yoshizawa from Hokkaido University in Japan. , During ...
(Date:4/17/2014)... the genetic information of DNA is used to ... numerous different functions in living organisms. Messenger RNA ... expression, by relating the genetic information of DNA ... , By examining the different types and ... at a given time, researchers can determine which ...
Breaking Biology News(10 mins):Structure of sodium channels different than previously believed 2In sex-reversed cave insects, females have the penises 2Rapid and accurate mRNA detection in plant tissues 2
... rapidly read the genomes of entire communities of microbes, ... the jumbled reams of data. In a paper appearing ... headed by researchers at the University of Washington and ... JGI) describes a novel approach for extracting single genomes ...
... LANSING, Mich. Michigan State University scientists, armed with ... Web-based genomic database of information on crops that can ... allow us to create better biofuel crops," said C. ... leader. "Right now, about half of the biofuel crops ...
... In the event of a standoff between the United ... if elected president, know enough about the physics of ... the nation toward reduced greenhouse gas emissions, would John ... America,s carbon footprint? If not, University of California, ...
Cached Biology News:Analysis of Lake Washington microbes shows the power of metagenomic approaches 2Analysis of Lake Washington microbes shows the power of metagenomic approaches 3MSU to create genomic clearinghouse for biofuel crops 2New book tutors future presidents and public on science behind the headlines 2New book tutors future presidents and public on science behind the headlines 3New book tutors future presidents and public on science behind the headlines 4New book tutors future presidents and public on science behind the headlines 5
...
... inhibition of RNase A-type ribonucleases Product Description: ... nonhuman origin that binds noncovalently and inactivates ... B, and C). It does not interfere ... or CL3. QIAGEN RNase Inhibitor inhibits greater ...
...
... Radiochemical Purity is >95%\nNEN Radiolabeled Ligands\n\nReceptor-related ... continual availability of new radiolabeled ligands selected ... offers a wide range of products and ... including over 400 state-of-the-art radioligands. If you ...
Biology Products: